En développement
Santé·avant-hierRésumé IA
FDA Advisers Review Experimental Peptide Therapies for Compounding Approval
FDA advisers are meeting for two days to review evidence for seven experimental peptide therapies, including TB-500, BPC-157, and MOTs-C, to determine if they can be compounded by specialized pharmacies despite FDA scientists' recommendations against approval due to limited human data.
N
NPR News2 min de lecture
